Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any sex
• People who have been diagnosed with a specific type of lymphoma called CD20-positive marginal zone lymphoma (which includes MALT, SMZL, and NMZL subtypes), confirmed by a tissue test, with at least one measurable area of disease
• People whose lymphoma is at an advanced stage (Stage III or IV) and has been assessed as needing treatment
• People who have not previously received any systemic (whole-body) treatment for this lymphoma — though prior local treatments such as surgery, radiotherapy, or certain antibiotic or antiviral therapies are acceptable if the disease later came back or was not suitable for further local treatment
• People whose general physical functioning falls within an acceptable range on a standard medical scale (ECOG score of 0–2, meaning the person is fully active to partially restricted but able to care for themselves)
• People whose blood counts, liver function, kidney function, and other organ measures fall within the required ranges set by the trial (confirm with trial site for specific values)
• People whose blood clotting levels are within an acceptable range
• People whose expected survival is at least 12 months
• People who are willing and able to provide written consent before any trial screening begins

Who may not be able to join:

• People who currently have, or have previously had, another cancer — unless it was treated with the intent to cure and there has been no sign of it returning or spreading in the past 5 years
• People whose lymphoma has spread to the central nervous system (brain or spinal cord), or whose lymphoma has changed into a more aggressive (high-grade) form
• People with serious or uncontrolled heart conditions, including moderate-to-severe heart failure, unstable chest pain, a heart attack within the past 6 months, certain heart rhythm problems, a weakened heart pump (reduced ejection fraction), certain types of heart muscle disease, a history of significant abnormalities in heart electrical activity, coronary artery disease requiring medication, or blood pressure that remains poorly controlled despite multiple medications
• People who have had active bleeding within the past 2 months, are currently using blood-thinning medications, or have any condition the trial doctor considers a significant bleeding risk
• People who have had a blood clot in a deep vein or in the lungs within the past 6 months
• People who have previously received an organ transplant or a bone marrow transplant from a donor
• People who have had major surgery within the past 6 weeks, or minor surgery within the past 2 weeks (placement of a vascular access device is not counted)
• People with an active infection requiring treatment, or with uncontrolled hepatitis B, hepatitis C, HIV/AIDS, or other serious infectious diseases
• People with serious ongoing lung conditions such as pulmonary fibrosis, interstitial pneumonia, or radiation- or drug-related lung damage
• People who have previously been treated with certain targeted therapies known as BTK inhibitors, BCR pathway inhibitors (such as PI3K or Syk inhibitors), or BCL-2 inhibitors
• People who are pregnant, breastfeeding, or who are unwilling to use effective contraception if there is a possibility of pregnancy
• People who are currently taking certain medications that strongly affect how the body processes drugs (specifically moderate or strong CYP3A inhibitors, or strong CYP3A inducers) — (confirm specific medications with trial site)
• People who have any other condition that the trial doctor considers would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.